Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €3.6 billion aggregate principal amount of senior notes in three series, consisting of €1.4 billion aggregate principal amount of 0.375% senior notes due 2019, €1.45 billion aggregate principal amount of 1.375% senior notes due 2024 and €750 million aggregate principal amount of 2.125% senior notes due 2028. AbbVie intends to use the net proceeds from the offerings to repay all or part of its 1.75% senior notes due 2017.

Headquartered in Chicago, Illinois, AbbVie is a global research-based biopharmaceutical company that develops and markets advanced therapies that address some of the world’s most complex and serious diseases. AbbVie products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; hepatitis C; human immunodeficiency virus; endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions, such as low testosterone.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Ferrell Maguire Keel and Rafeeq Khazin. The tax team included partner David H. Schnabel and associate Christopher A. Baratta. Partner Pritesh P. Shah and associate Paul S. Lee provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post